Endocrine Abstracts

Cosyntropin stimulation test is the gold diagnostic standard used to test for NCAH. Genetic testing is not currently considered to be the primary diagnostic tool for NCAH. Still, it may be helpful in establishing a diagnosis if other results are unequivocal or for genetic counselling purposes. The study aimed at verifying the currently accepted threshold of 17-hydroxyprogesterone (17OHP) level (3 2.0 ng/ml) at which a cosyntropin stimulation test should be performed...

BackgroundSomatostatin analogues (SSA) (octreotide and lanreotide) are recommended as a first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of them are usually used in injection repeated every 4 weeks.The study objectiveWas to compare the way of SSA administration (injection performed by profession...

Background: Children with pre-symptomatic type 1 diabetes (T1D) can be identified through testing for circulating islet autoantibodies (AAb). Identifying children at risk reduces diabetic ketoacidosis at onset and allows participation in trials aiming for immunoprevention. The EarLy Surveillance for Autoimmune diabetes (ELSA) study is exploring feasibility and acceptability of UK paediatric general population screening.Methods:</...

Background: GI neuroendocrine tumors express somatostatin (SSTR) receptors, and the radioloabeled SSTR analog Lu-177-DOTATATE is an FDA-approved systemic treatment for those with metastatic disease. Olaparib is a poly (ADP-ribose) polymerase inhibitor (PARPi) which inhibits cells from repairing damaged DNA, especially single-stranded DNA breaks caused by beta particle emissions from the radioactive decay of Lu-177. We report the first results of a phase 1/2 study evaluating th...

Background: Metastatic GI Neuroendocrine Tumors (GI-NET) and pheochromocytoma/paraganglioma (PPGL) are are tumors which overexpresses somatostatin receptors (SSTR) and can be treated with targeted radioligand therapy (RLT) such as Lu-177-DOTATATE. However, despite demonstrated clinical efficacy at stabilizing tumor growth, durable response is very rare and almost all patients inevitably progresses at some time after treatment. Good systemic therapy options after beta-emiting R...

Introduction: Ectopic Cushing’s syndrome (ECS) is a rare disease with limited and error-prone published data on the epidemiology, clinical presentation and diagnosis of ECS.Objectives: This study aims to examine the clinical course of patients with ECS in relation to the primary tumor localization.Methods: Thirty-five consecutive ECS patients at a tertiary clinical center were analyzed. The clinical, biochemical (including CRH...

Introduction: The good expression of somatostatin receptors in neuroendocrine tumor tissue enables effective treatment with peptide receptor radionuclide therapy (PRRT). To date, there is no clear consensus on the optimal PRRT arrangement due to the possibility of the use of different radiopharmaceutical regimens. In theory, the simultaneous use of two radionuclides (90Y and 177Lu) with different energy and radiation ranges should be more effective than monotherapy. The main o...

Aim/Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective treatment for disseminated neuroendocrine tumors (NETs) expressing somatostatin receptors. Despite many published studies, the consensus on the optimal PRRT treatment algorithm has not been reached yet. The main objective of the DUONEN multicenter, randomized, phase III study (EUDRACT No: 2020-006068-99) is the development of a dosimetry-based personalized PRRT algorithm. The second goal includes th...

The recent discovery of brown adipose tissue (BAT) in adult humans, which generates heat to maintain body temperature in a cold environment, offers an exciting new strategy to treat obesity and metabolic disease, but our knowledge of human BAT activation is limited. To identify novel pathways regulating human BAT, we undertook RNA sequencing of human brown and white adipocytes. The gene SLC6A4 (encoding the serotonin transporter SERT) was one of the most highly differ...

Background: The excessive secretion of parathormone by parathyroid glands is a common disorder known as hyperparathyroidism. With a prevalence of 0.1-0.4 percent in the general population and 2-4 percent in post-menopausal women, primary hyperparathyroidism is the third most frequently reported endocrine disorder. According to estimates, the prevalence of primary hyperparathyroidism has escalated in recent years, probably due to the increasing rate of parathormone and calcium ...